Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise for cervical cancer before surgery

NCT ID NCT07055399

Disease control Sponsor: Fujian Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with chemotherapy before surgery can help shrink tumors in people with locally advanced cervical cancer. The study will enroll 43 participants and measure how many have no cancer cells left at the time of surgery. It is an early-stage study, so results are not yet proven.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iparomlimab and tuvonralimab (a dual PD-1/CTLA-4 blocker) plus cisplatin and nab-paclitaxel chemotherapy
What this could lead to
If successful, this approach could offer a more effective way to shrink tumors before surgery, potentially improving long-term outcomes for patients with locally advanced cervical cancer.
What could go wrong
This is a small, early-phase trial (43 participants) with no control group, so results may not be definitive. The drug combination may cause significant side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 43 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1、Written informed consent * 2、18-70 years old * 3、Adequate organ function and ECOG of 0 \~1 * 4、Without systemic therapy at the time of enrollment * 5、FIGO 2018 stage IB3, IIA2, or IIIC1r * 6、Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix * 7、Measurable lesions could be defined by RECIST v1.1 * 8、Willing to get blood/ tumor tissue tested * 9、Patients who observed the rules about the scheduled visit, study schedule, and medical examination * 10、The function of major organs is normal, and the following criteria are met: * 10.1 Blood routine examination must meet: (no blood transfusion within 14 days) Hb≥90g/L: ANC≥1.5x10\^9/L; PLT≥100x10\^9/L; * 10.2 The biochemical examination must meet the following standards BIL \< 1.5 × ULN; ALT and AST \< 2.5xULN; ALB≥ 28 g/L * 11、Patients who are willing and able to comply with visiting arrangements, treatment plans, laboratory tests, and other research procedures. Exclusion Criteria: * 1、History of other malignancies within 3 years * 2、Participate in other clinical trials at the same time * 3、Active autoimmune disease, which needs systemic therapy * 4、Uncontrolled infection, which needs systemic therapy * 5、History of allogeneic tissue/solid organ transplant * 6、Serious illness, such as severe mental disorders, cardiac disease, coagulation disorders, digestive system disease, etc * 7、Active HBV, HCV, or HIV infection * 8、Pregnant or lactating female patients * 9、Drug or alcohol abuse * 10、 Unable or unwilling to sign the informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced cervical cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.